Contact
Please use this form to send email to PR contact of this press release:
Genmab Announces U.S. FDA Approval of Arzerra(r) (ofatumumab) as Extended Treatment for Recurrent or Progressive CLL
TO:
Please use this form to send email to PR contact of this press release:
Genmab Announces U.S. FDA Approval of Arzerra(r) (ofatumumab) as Extended Treatment for Recurrent or Progressive CLL
TO: